drug pricing

Commercial Protectionism vs. Affordable Pharmaceuticals: Navigating the Complex Landscape of U.S. Healthcare Policy

Brian Rogers0153 views

In the ongoing debate between commercial protectionism and the accessibility of affordable pharmaceuticals, the United States finds itself at a critical juncture. While the FDA’s stringent regulations on imported generics from countries like India are justified by health concerns, there is a growing perception that these measures increasingly serve commercial interests. Critics argue that the influence of Big Pharma has led to policies that prioritize corporate profits over consumer welfare, resulting in higher healthcare costs for Americans. This article explores the origins of these regulatory measures, the role of pharmaceutical lobbying, and the economic impacts of protectionism, calling for reforms to balance safety with affordability and accessibility.

Read more

Beyond the Patents: The Monopoly Practices of Big Pharma and What American Consumers Aren’t Told

Brian Rogers0207 views

The high cost of prescription drugs in the U.S. is driven by Big Pharma’s patent practices and strategic blocking of affordable generic medications, especially from India. This article reveals how evergreening tactics, intense lobbying, and restrictive FDA regulations keep drug prices artificially high and prevent the entry of cheaper alternatives. These monopoly practices significantly impact consumers, leading to high healthcare costs and limited access to essential medications. Organizations like Ashvin Medicara play a crucial role in advocating for the importation of safe and affordable generics, challenging the power of Big Pharma and supporting policy changes for better healthcare access.

Read more

How Payment Processors and Shadow Regulation Prevent Americans from Accessing Affordable Generic Pharmaceuticals from India

Brian Rogers0170 views

Americans seeking affordable healthcare solutions often turn to generic pharmaceuticals from countries like India. However, they face significant barriers in using common payment methods such as Visa, MasterCard, PayPal, and Venmo to purchase these medications. This article explores how shadow regulation, particularly by LegitScript, influences payment processors to block transactions related to online pharmacies, and how Big Pharma and government collusion perpetuate these obstacles. The narrative portrays online generic pharmacies as fraudulent, while in reality, this is a form of commercial protectionism benefitting a select few. By recognizing these challenges and advocating for transparency, consumers can better navigate the complex landscape of pharmaceutical access.

Read more

Undermining the Foundations: How Big Pharma and U.S. Politicians Contradict American Ideals

Brian Rogers0180 views

In the U.S., the foundational principles of freedom, equality, and the pursuit of happiness are undermined by the collusion between big pharma, congressional elites, and government agencies. This alliance prioritizes profit over patient welfare, restricting access to affordable medications and violating constitutional promises of life and liberty. To realign with American ideals, there must be reforms to limit pharmaceutical influence, promote competition, and prioritize patient-centric policies. It’s crucial to advocate for a healthcare system that truly serves its people and reflects the nation’s founding values.

Read more

The Stark Contrast: The True Cost of Medication Production vs. Retail Prices in the U.S.

Brian Rogers0160 views

The significant disparity between production costs and retail prices for medications in the U.S. highlights critical issues in market dynamics, patent laws, and regulatory frameworks favoring pharmaceutical companies. For example, the cost to manufacture insulin is around $2 to $6 per vial, but its U.S. retail price can exceed $200. Such discrepancies result in elevated healthcare expenses for patients, underscoring the potential benefits of considering generics and international alternatives to manage costs more effectively.

Read more